Cargando…

1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States

BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (i...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilishvili, Tamara, Gierke, Ryan, Farley, Monica M, Schaffner, William, Thomas, Ann, Reingold, Art, Harrison, Lee, Holtzman, Corinne, Burzlaff, Kari, Petit, Susan, Herlihy, Rachel, Torres, Salina, Beall, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777437/
http://dx.doi.org/10.1093/ofid/ofaa439.1651
_version_ 1783630901475803136
author Pilishvili, Tamara
Gierke, Ryan
Farley, Monica M
Schaffner, William
Thomas, Ann
Reingold, Art
Harrison, Lee
Holtzman, Corinne
Burzlaff, Kari
Petit, Susan
Herlihy, Rachel
Torres, Salina
Beall, Bernard
author_facet Pilishvili, Tamara
Gierke, Ryan
Farley, Monica M
Schaffner, William
Thomas, Ann
Reingold, Art
Harrison, Lee
Holtzman, Corinne
Burzlaff, Kari
Petit, Susan
Herlihy, Rachel
Torres, Salina
Beall, Bernard
author_sort Pilishvili, Tamara
collection PubMed
description BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (isolation of pneumococcus from sterile sites) were identified through CDC’s Active Bacterial Core surveillance during 1998-2018. Isolates were serotyped by Quellung or whole genome sequencing and classified as PCV13-type and non-vaccine-type (NVT). Incidence rates (cases/100,000) were calculated using U.S. Census Bureau population denominators. RESULTS: From 1998 through 2018, overall IPD rates among children aged < 5 years decreased by 93% (from 95 to 7 cases/100,000). PCV13-type IPD decreased by 98% (from 88 to 2 cases/100,000). Among adults aged ≥ 65 years, overall IPD rates decreased by 60% (from 61 to 25 cases/100,000). PCV13-type IPD rates declined 86% (from 46 to 7 cases/100,000). Declines were most dramatic in the years following PCV7 introduction, with additional declines after PCV13 introduction in children (Figures 1 and 2). Serotypes 3, 19A, and 19F caused most of the remaining PCV13-type IPD. NVT IPD rates did not change significantly among children. Among adults aged 50-64 years, NVT IPD increased by 83% (from 6 to 12 cases/100,000) (p< 0.01). Among adults aged ≥ 65 years, NVT IPD increased by 22% (from 15 to 18 cases/100,000) (p< 0.01). The most common NVTs in 2018 were 22F (10% of all IPD), 9N (7%) and 15A (5%). Among children, the proportion of cases with meningitis increased from 5% to 14% (p< 0.01), and the proportion with pneumonia/empyema increased from 17% to 31% (p< 0.01). Among adults, the proportion of cases with meningitis did not change (3%), while the proportion with pneumonia/empyema increased from 72% to 76% (p=0.01). Figure 1: Incidence of invasive pneumococcal disease among children aged < 5 years, 1998-2018 [Image: see text] Figure 2: Incidence of invasive pneumococcal disease among adults aged ≥ 65 years, 1998-2018 CONCLUSION: Overall IPD incidence among children and adults decreased following PCV introduction for children, driven primarily by reductions in PCV-type IPD. NVT IPD increased in older adults, but these increases did not eliminate reductions from PCV13-type IPD. [Image: see text] DISCLOSURES: Lee Harrison, MD, GSK (Consultant)Merck (Consultant)Pfizer (Consultant)Sanofi Pasteur (Consultant)
format Online
Article
Text
id pubmed-7777437
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77774372021-01-07 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States Pilishvili, Tamara Gierke, Ryan Farley, Monica M Schaffner, William Thomas, Ann Reingold, Art Harrison, Lee Holtzman, Corinne Burzlaff, Kari Petit, Susan Herlihy, Rachel Torres, Salina Beall, Bernard Open Forum Infect Dis Poster Abstracts BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (isolation of pneumococcus from sterile sites) were identified through CDC’s Active Bacterial Core surveillance during 1998-2018. Isolates were serotyped by Quellung or whole genome sequencing and classified as PCV13-type and non-vaccine-type (NVT). Incidence rates (cases/100,000) were calculated using U.S. Census Bureau population denominators. RESULTS: From 1998 through 2018, overall IPD rates among children aged < 5 years decreased by 93% (from 95 to 7 cases/100,000). PCV13-type IPD decreased by 98% (from 88 to 2 cases/100,000). Among adults aged ≥ 65 years, overall IPD rates decreased by 60% (from 61 to 25 cases/100,000). PCV13-type IPD rates declined 86% (from 46 to 7 cases/100,000). Declines were most dramatic in the years following PCV7 introduction, with additional declines after PCV13 introduction in children (Figures 1 and 2). Serotypes 3, 19A, and 19F caused most of the remaining PCV13-type IPD. NVT IPD rates did not change significantly among children. Among adults aged 50-64 years, NVT IPD increased by 83% (from 6 to 12 cases/100,000) (p< 0.01). Among adults aged ≥ 65 years, NVT IPD increased by 22% (from 15 to 18 cases/100,000) (p< 0.01). The most common NVTs in 2018 were 22F (10% of all IPD), 9N (7%) and 15A (5%). Among children, the proportion of cases with meningitis increased from 5% to 14% (p< 0.01), and the proportion with pneumonia/empyema increased from 17% to 31% (p< 0.01). Among adults, the proportion of cases with meningitis did not change (3%), while the proportion with pneumonia/empyema increased from 72% to 76% (p=0.01). Figure 1: Incidence of invasive pneumococcal disease among children aged < 5 years, 1998-2018 [Image: see text] Figure 2: Incidence of invasive pneumococcal disease among adults aged ≥ 65 years, 1998-2018 CONCLUSION: Overall IPD incidence among children and adults decreased following PCV introduction for children, driven primarily by reductions in PCV-type IPD. NVT IPD increased in older adults, but these increases did not eliminate reductions from PCV13-type IPD. [Image: see text] DISCLOSURES: Lee Harrison, MD, GSK (Consultant)Merck (Consultant)Pfizer (Consultant)Sanofi Pasteur (Consultant) Oxford University Press 2020-12-31 /pmc/articles/PMC7777437/ http://dx.doi.org/10.1093/ofid/ofaa439.1651 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Pilishvili, Tamara
Gierke, Ryan
Farley, Monica M
Schaffner, William
Thomas, Ann
Reingold, Art
Harrison, Lee
Holtzman, Corinne
Burzlaff, Kari
Petit, Susan
Herlihy, Rachel
Torres, Salina
Beall, Bernard
1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title_full 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title_fullStr 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title_full_unstemmed 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title_short 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
title_sort 1470. epidemiology of invasive pneumococcal disease (ipd) following 18 years of pneumococcal conjugate vaccine (pcv) use in the united states
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777437/
http://dx.doi.org/10.1093/ofid/ofaa439.1651
work_keys_str_mv AT pilishvilitamara 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT gierkeryan 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT farleymonicam 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT schaffnerwilliam 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT thomasann 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT reingoldart 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT harrisonlee 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT holtzmancorinne 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT burzlaffkari 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT petitsusan 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT herlihyrachel 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT torressalina 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates
AT beallbernard 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates